Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer-Reference-Cited by-同舟云学术

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Published:2019-02-22 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Borrero-Palacios A.,Cebrián A.,Gómez del Pulgar M. T.,García-Carbonero R.,Garcia-Alfonso P.,Aranda E.,Elez E.,López-López R.,Cervantes A.^ORCID,Valladares M.,Nadal C.,Viéitez J. M.,Guillén-Ponce C.^ORCID,Rodríguez J.,Hernández I.,García J. L.,Vega-Bravo R.,Puime-Otin A.,Martínez-Useros J.,Del Puerto-Nevado L.,Rincón R.,Rodríguez-Remírez M.,Rojo F.,García-Foncillas J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-39291-2.pdf

Reference40 articles.

1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon (France)

2. 2013 [accessed 2018 January 31]. http://globocan.iarc.fr .

3. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. ARCI: OMS; [accessed 2018 January 31] http://globocan.iarc.fr/Default.aspx .

4. Cartwright, T. H. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin. Colorectal Cancer. 11, 155–166 (2012).

5. Attar, B. M., Atten, M. J. & Holian, O. MAPK activity is down-regulated in human colon adenocarcinoma:correlation with PKC activity. Anticancer Res. 16, 395–399 (1996).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological Assessment of Recent Immunotherapy for Colorectal Cancer;Immunological Investigations;2023-10-09

2. Immunological assessment of recent immunotherapy for colorectal cancer.;2023-08-16

3. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC;Pharmaceutics;2022-11-15

4. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era;International Journal of Molecular Sciences;2021-07-19

5. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer;Cancers;2021-04-17